Published

Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney's lesions.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: European archives of psychiatry and clinical neuroscience
Date: 2024-06-01
Source: PubMed
DOI: 10.1007/s00406-023-01699-3
PubMed: 37934233

Authors

Iorgu AM Vasilescu AN Pfeiffer N Spanagel R Mallien AS Inta D Gass P

Watch author

Derived topics and classifications

psilocybin Receptor Pharmacology Biomarkers Toxicity Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Psilocybin does not induce the vulnerability marker HSP70 in neurons susceptible to Olney's lesions.2024-06-01

Related papers

Psilocybin Versus Ketamine - Fast Acting Antidepressant Strategies in Treatment-resistant DepressionClinicalTrials.gov · 2022-05-20 Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe DepressionClinicalTrials.gov · 2017-12-21 Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy ParticipantsClinicalTrials.gov · 2026-04-02 Investigation of Psychedelic Effects in Psychoactive SubstancesClinicalTrials.gov · 2026-02-23 Psilocybin vs Ketamine for Alcohol Use DisorderClinicalTrials.gov · 2025-11-28 Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of LifeClinicalTrials.gov · 2025-11-25 Psilocybin-Assisted vs Ketamine-Assisted Psychotherapy for Alcohol Use DisorderClinicalTrials.gov · 2025-11-17